All entries for: Sarepta Therapeutics

May 6, 2026

Sarepta Therapeutics

Neutral Outlook

Cambridge, MA
501-1,000 employees

For example, the Inflation Reduction Act (“IRA”), passed in 2022, IRA has had and will likely continue to have a significant impact on the pharmaceutical industry. In 2025, the current presidential administration issued two executive orders with multiple directives aimed at lowering drug prices.

Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic
July 18, 2025

Sarepta Therapeutics

Layoffs

Cambridge, MA
501-1,000 employees

After a difficult season that has seen two deaths linked to Sarepta Therapeutics’ Duchenne muscular dystrophy treatment Elevidys, the Cambridge, Massachusetts–based biotech is letting go of more than a third of its workforce and adding a black box warning for acute liver injury and acute liver failure to the gene therapy. In a July 16 announcement, Sarepta revealed it will part with around 500 employees after a strategic review and focus its pipeline on “high-impact programs, prioritizing potentially best-in-class siRNA platform assets.” These include programs for facioscapulohumeral muscular dystrophy, idiopathic pulmonary fibrosis and Huntington’s disease.

Disease Area: Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
Scroll to Top